NC-PERCONA
20.8.2024 14:31:27 CEST | Business Wire | Press release
Percona, a global leader in enterprise-grade open source database software and services, today announced the addition of two preeminent technology business leaders – John Newton, Co-Founder of Alfresco and Documentum, and Rob Young, a veteran of the open source software ecosystem – as independent directors to its board. The appointments expand the wealth of business strategy, industry expertise and strategic counsel the Percona board offers CEO Ann Schlemmer and her leadership team.
John Newton brings over 40 years of experience in the enterprise software industry, having played a pivotal role in the development and success of numerous companies. A serial entrepreneur, John co-founded Documentum, which was acquired by EMC in 2003, and Alfresco, an open source platform for information management, which had a successful exit with its sale to Hyland Software in 2020. John began his career as one of the founding engineers at Ingres Corporation, where he led the development of their database management system. His innovative contributions to data and information management have earned him several prestigious awards, including recognition as a Technology Pioneer at the World Economic Forum in Davos in 2006 and the Award of Merit from the Association for Intelligent Information Management (AIIM) in 2023. John holds a BS in Electrical Engineering and Computer Science from the University of California, Berkeley, and has served on the boards of several leading companies, including Alfresco, Wideworks, and AIIM.
Rob Young is a seasoned business and technology executive with four decades of experience in building and delivering enterprise solutions through an open source development and delivery model. During his career, Rob has held key technical and leadership positions across various industries, including finance, transportation, healthcare, public utilities, and commercial software and services. Rob has been a driving force in establishing open source software as a trusted foundation for digital transformation. He was instrumental in developing growth strategies and business models focused on value-added differentiation and customer satisfaction in numerous strategic roles at MySQL AB, MongoDB, Percona, RedHat, and DigitalOcean. Notably, while with MySQL AB, Rob led the design, development, and delivery of MySQL Enterprise, which quadrupled the company's revenue in just two years and culminated in a $1 billion acquisition by Sun Microsystems. Rob holds a Bachelor of Science in Economics and Math from the University of Louisville and resides in Louisville, KY.
“We are honored to welcome John Newton and Rob Young to our board,” said Ann Schlemmer, CEO of Percona. “Their extensive experience and deep understanding of the industry will be invaluable as we continue to innovate and deliver world-class solutions to our customers. Their leadership and vision will be crucial as we navigate the opportunities and challenges ahead, ensuring we maintain the highest standards of corporate governance.”
These appointments come at a pivotal time for Percona as the company reaffirms its commitment to cloud-native development with the introduction of Percona Everest and expands its footprint into the Redis ecosystem through its involvement with the Linux Foundation’s Valkey Project. With the addition of John Newton and Rob Young, Percona is well-positioned to accelerate growth and continue its mission of empowering enterprises with robust, reliable, and scalable open source database solutions.
About Percona
Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available. Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815431864/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom